Verseau unveils tumor macrophage reprogramming strategy
Verseau debuts with $50M, therapies that make tumor-associated macrophages pro-inflammatory
Verseau is aiming to treat solid tumor patients who don't respond to T cell-targeting agents by reprogramming tumor-associated macrophages to make them immuno-stimulatory.
Eight months after announcing a collaboration with 3SBio Inc. (HKSE:1530), Verseau Therapeutics Inc. unveiled its first macrophage checkpoint program, anti-PSGL-1 mAb VTX-0811, and $50 million in financing on Monday. The company also appointed George Golumbeski, former Celgene Corp. (NASDAQ:CELG) EVP, its chairman.
Verseau was founded in 2017 by serial entrepreneur Robert Langer; Daniel Anderson; Igor Feldman, head of computational biology;